Could cause temporary or reversible harm; serious harm is unlikely.
Lack of assurance of sterility. Bacterial contamination detected in some media fill units
| Brand name | HALOPERIDOL DECANOATE |
| Generic name | HALOPERIDOL DECANOATE |
| Active ingredient(s) | HALOPERIDOL DECANOATE |
| Distributed by / for | BluePoint Laboratories |
| NDC | 68001-580-41 |
| Full product label | Haloperidol Decanoate Injection, 50mg/mL* , 1 mL Single-Dose Vial, Rx only, Manufactured by Somerset Therapeutics Limited, 54/1, Boodhihal Village, Nelamangala, Bangalore - 562123, Karnataka, India, Manufactured for: BluePoint Laboratories, NDC 68001-580-41. |
| Recalling firm | Amerisource Health Services LLC |
| Distribution | Nationwide in the USA |
| Quantity | 2,110 vials |
| Recall initiated | 2025-04-02 |
| Report date | 2025-04-30 |
| Recall completed | — |
| Recall number | D-0367-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗